ClinicalTrials.gg
CompletedNCT01148615Updated Jan 13, 2012

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

A Phase 1 interventional study of Aflibercept (AVE0005) and Docetaxel (XRP6976) in Neoplasm Malignant, sponsored by Sanofi. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-13.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Primary Objective:

  • To confirm the dose of aflibercept in western studies by assessing the dose-limiting toxicity (DLT) of intravenous (IV) aflibercept when administered in combination with docetaxel given intravenously every 3 weeks in Chinese patients with solid tumors.

Secondary Objectives:

  • To assess the safety profile of intravenous (IV) aflibercept when administered in combination with docetaxel
  • To determine the pharmacokinetics of IV aflibercept and docetaxel when administered in combination
  • To make a preliminary assessment of antitumor effects of the combination of docetaxel plus aflibercept in patients with evaluable disease
  • To evaluate the immunogenicity of IV aflibercept
  • To measure endogenous free Vascular Endothelial Growth Factor (VEGF)
Read the detailed description

The duration of screening, treatment, and follow-up are within 21 days, 3 weeks/cycle, and 90 days after the last aflibercept administration. Patients will be administered aflibercept in combination with docetaxel until when/if a definitive treatment discontinuation criterion is met such as progressive disease, unacceptable toxicity or patient refusal to continue.

02

Conditions studied

  • Neoplasm Malignant

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed solid that or unresectable for which standard curative measures do not exist, but for which docetaxel treatment is appropriate.

Exclusion criteria

Exclusion criteria :

  • Squamous histology/cytology lung cancer
  • Need for a major surgical procedure or radiation therapy during the study
  • Treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an agent within 28 days
  • Cumulative radiation therapy to >25% of the total bone marrow
  • History of
  • (ECOG)>1
  • Prior docetaxel treatment but have not been appropriate for safety reasons
  • Inadequate organ and bone marrow function
  • Uncontrolled hypertension
  • Evidence of bleeding diathesis or underlying coagulopathy

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Aflibercept/ docetaxel

    Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel. Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks

    Drug: Aflibercept (AVE0005) · Drug: Docetaxel (XRP6976)

Interventions

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT)

    Time frame: 3 weeks (cycle 1)

Secondary outcomes

  1. Global safety profile based on treatment emergent adverse events, serious adverse events, and laboratory abnormalities

    Time frame: Up to 30 days after last administration within a maximum follow up of 18 months

  2. Pharmacokinetic parameters of aflibercept

    Time frame: up to last aflibercept administration +90 days

  3. Pharmacokinetic parameters of docetaxel

    Time frame: cycle 1

  4. Tumor response rate as calculated by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: up to a maximum follow-up of 18 months

  5. Immunogenicity of Aflibercept

    Time frame: up to last aflibercept administration+90 days

  6. Endogenous free VEGF

    Time frame: up to last aflibercept administration+30 days

07

Study locations

1 site
  • Sanofi-Aventis Investigational Site Number 156001
    Guangzhou, 510060, China
08

References and documents

Publications

  • Huang Y, Zou BY, Zhao LP, Zhao HY, Zhao YY, Xue C, Zhang JW, Xu F, Chen LK, Liu JL, Hu ZH, Wu X, Zhang J, Ma YX, Wei CL, Ma Y, Zhang L. Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors. Future Oncol. 2014 Dec;10(16):2579-91. doi: 10.2217/fon.14.206. PubMed 25531046 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Sep 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2010
First posted
Jun 22, 2010
Start
Jul 2010
Primary completionActual
Sep 2011
CompletionActual
Dec 2011
Last update
Jan 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01148615
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Jul 2010
Primary completion
Sep 2011
Completion
Dec 2011
Last update
Jan 13, 2012

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aflibercept · Docetaxel

Start the discussion